Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Last year, Keytruda generated ... approved a $30.2 million grant to Merck, contingent on the company’s decision to set up operations at the Chestnut Run Innovation & Science Park (CRISP ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

A groundbreaking ceremony was held at Chestnut Run Innovation & Science Park on April 29, bringing together business and government officials to celebrate the milestone. Merck’s facility ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

The site will also have the capability to manufacture KEYTRUDA ® (pembrolizumab), and ... Davis, chairman and chief executive officer, Merck. The new facility, located at Chestnut Run Innovation & ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

A groundbreaking ceremony was held at Chestnut Run Innovation & Science Park on April 29, bringing together business and government officials to celebrate the milestone. Merck’s facility ...